 MELBOURNE, Australia, Jan. 04, 2022 GLOBE NEWSWIRE -- Opthea Limited ASX:OPT, a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Dr Megan Baldwin, the Companys Chief Executive Officer, will participate in the H.C. Wainwright BIOCONNECT Conference, being held virtually from January 10-13, 2022. 